|
US7034132B2
(en)
|
2001-06-04 |
2006-04-25 |
Anderson David W |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
|
US6953682B2
(en)
|
2000-02-10 |
2005-10-11 |
Millennium Pharmaceuticals, Inc. |
Nucleic acid sequences encoding adenylate kinase, phospholipid scramblase-like, DNA fragmentation factor-like, phosphatidylserine synthase-like, and atpase-like molecules and uses therefor
|
|
US20040082051A1
(en)
*
|
2000-12-14 |
2004-04-29 |
Zhimin Zhu |
Regulation of human uridine kinase
|
|
US20040072997A1
(en)
*
|
2000-12-20 |
2004-04-15 |
Alsobrook John P. |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
|
AU2002250143A1
(en)
*
|
2001-03-16 |
2002-10-03 |
Eli Lilly And Company |
Lp mammalian proteins; related reagents
|
|
US7033790B2
(en)
|
2001-04-03 |
2006-04-25 |
Curagen Corporation |
Proteins and nucleic acids encoding same
|
|
NZ531674A
(en)
|
2001-09-18 |
2009-03-31 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of tumor
|
|
WO2003083117A2
(en)
*
|
2002-04-01 |
2003-10-09 |
Asahi Kasei Pharma Corporation |
Vascularization controlling gene
|
|
EP1565488A4
(en)
*
|
2002-05-15 |
2007-10-03 |
Avalon Pharmaceuticals |
CANCER-RELATED GENE AS A TARGET FOR CHEMOTHERAPY
|
|
ATE500326T1
(en)
*
|
2002-06-06 |
2011-03-15 |
Oncotherapy Science Inc |
GENES AND PROTEINS RELATED TO HUMAN COLON CANCER
|
|
GB0215295D0
(en)
*
|
2002-07-02 |
2002-08-14 |
Inpharmatica Ltd |
Proteins
|
|
CA2520001A1
(en)
*
|
2003-03-26 |
2004-10-07 |
Novartis Ag |
Cyclic amp response element activator proteins and uses related thereto
|
|
US7361747B2
(en)
*
|
2003-05-22 |
2008-04-22 |
The University Of Hong Kong |
Isolation and characterization of the precursor virus of human SARS virus: SARS-associated corona virus-like virus
|
|
GB0320878D0
(en)
*
|
2003-09-05 |
2003-10-08 |
Celltech R&D Ltd |
A protein involved in carcinoma
|
|
EP1689888A2
(en)
|
2003-10-23 |
2006-08-16 |
Illumigen Biosciences Inc. |
Detection of mutations in a gene associated with resistance to viral infection, oas1
|
|
NZ547633A
(en)
|
2003-11-06 |
2010-08-27 |
Seattle Genetics Inc |
Monomethylvaline compounds capable of conjugation to ligands
|
|
AU2005249490B2
(en)
|
2004-06-01 |
2010-07-29 |
Genentech, Inc. |
Antibody drug conjugates and methods
|
|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
|
KR101270829B1
(en)
|
2004-09-23 |
2013-06-07 |
제넨테크, 인크. |
Cystein engineered antibodies and conjugates
|
|
WO2006097335A1
(en)
*
|
2005-03-18 |
2006-09-21 |
Universität Zürich |
A new element of the wg/wnt signaling pathway
|
|
UA95446C2
(en)
|
2005-05-04 |
2011-08-10 |
Іллюміджен Байосайєнсіз, Інк. |
Mutations in oas1 genes
|
|
CA2621363C
(en)
|
2005-09-13 |
2015-07-07 |
National Research Council Of Canada |
Methods and compositions for modulating tumor cell activity
|
|
WO2009093246A2
(en)
*
|
2008-01-22 |
2009-07-30 |
Compugen Ltd. |
Novel clusterin derived peptide
|
|
IN2012DN03025A
(en)
|
2009-09-09 |
2015-07-31 |
Ct Se Llc |
|
|
US8802826B2
(en)
|
2009-11-24 |
2014-08-12 |
Alethia Biotherapeutics Inc. |
Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
|
|
EP2528625B1
(en)
|
2010-04-15 |
2013-07-10 |
Spirogen Sàrl |
Pyrrolobenzodiazepines and conjugates thereof
|
|
JP2013534520A
(en)
|
2010-06-08 |
2013-09-05 |
ジェネンテック， インコーポレイテッド |
Cysteine engineered antibodies and conjugates
|
|
US20120121595A1
(en)
*
|
2010-10-11 |
2012-05-17 |
University Of Southern California |
FRAGMENT OF SECRETED HEAT SHOCK PROTEIN-90ALPHA (Hsp90ALPHA) AS VACCINES OR EPITOPE FOR MONOCLONAL ANTIBODY DRUGS OR TARGET FOR SMALL MOLECULE DRUGS AGAINST A RANGE OF SOLID HUMAN TUMORS
|
|
CN103313990B
(en)
|
2010-11-17 |
2016-07-20 |
基因泰克公司 |
Alanyl maytansinol antibody coupling matter
|
|
CN103608684B
(en)
|
2011-05-12 |
2016-05-04 |
基因泰克公司 |
A Multiple Reaction Monitoring LC-MS/MS Method for the Detection of Therapeutic Antibodies in Animal Samples Using Framework Signature Peptides
|
|
RS54446B1
(en)
|
2011-10-14 |
2016-06-30 |
Medimmune Limited |
PIROLOBENZIDIAZEPINE AND ITS CONJUGATES
|
|
EP2817028A4
(en)
|
2012-02-22 |
2015-11-04 |
Alethia Biotherapeutics Inc |
Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
|
|
WO2013130093A1
(en)
|
2012-03-02 |
2013-09-06 |
Genentech, Inc. |
Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
|
|
WO2014057114A1
(en)
|
2012-10-12 |
2014-04-17 |
Adc Therapeutics Sàrl |
Pyrrolobenzodiazepine-anti-psma antibody conjugates
|
|
ES2530968T3
(en)
|
2012-10-12 |
2015-03-09 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
|
EP2906297B1
(en)
|
2012-10-12 |
2017-12-06 |
ADC Therapeutics SA |
Pyrrolobenzodiazepine-antibody conjugates
|
|
CA2887895C
(en)
|
2012-10-12 |
2019-10-29 |
Adc Therapeutics Sarl |
Pyrrolobenzodiazepine-anti-cd19 antibody conjugates
|
|
PT2906251T
(en)
|
2012-10-12 |
2017-12-04 |
Medimmune Ltd |
CONJUGATES OF PYRROLOBENZODIAZEPINA-ANTIBODY ANTI-CD22
|
|
TR201808051T4
(en)
|
2012-10-12 |
2018-06-21 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine antibody conjugates.
|
|
JP6270859B2
(en)
|
2012-10-12 |
2018-01-31 |
エイディーシー・セラピューティクス・エス・アー・エール・エルＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａｒｌ |
Pyrrolobenzodiazepine-antibody conjugate
|
|
CA2894961C
(en)
|
2012-12-21 |
2020-09-15 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
|
EA032986B1
(en)
|
2012-12-21 |
2019-08-30 |
Медимьюн Лимитед |
Pyrrolobenzodiazepines
|
|
NZ710745A
(en)
|
2013-03-13 |
2019-03-29 |
Genentech Inc |
Pyrrolobenzodiazepines and conjugates thereof
|
|
WO2014140174A1
(en)
|
2013-03-13 |
2014-09-18 |
Spirogen Sàrl |
Pyrrolobenzodiazepines and conjugates thereof
|
|
CA2904044C
(en)
|
2013-03-13 |
2020-03-31 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
EP3033111B1
(en)
|
2013-08-12 |
2019-03-13 |
Genentech, Inc. |
1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
|
|
US9956299B2
(en)
|
2013-10-11 |
2018-05-01 |
Medimmune Limited |
Pyrrolobenzodiazepine—antibody conjugates
|
|
US9950078B2
(en)
|
2013-10-11 |
2018-04-24 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
|
EP3054983B1
(en)
|
2013-10-11 |
2019-03-20 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
|
GB201317982D0
(en)
|
2013-10-11 |
2013-11-27 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
|
JP6671292B2
(en)
|
2013-12-16 |
2020-03-25 |
ジェネンテック， インコーポレイテッド |
Peptidomimetic compounds and antibody-drug conjugates thereof
|
|
MX2016007578A
(en)
|
2013-12-16 |
2016-10-03 |
Genentech Inc |
1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment.
|
|
BR112016013861A2
(en)
|
2013-12-16 |
2017-10-10 |
Genentech Inc |
drug and antibody conjugates, compounds, treatment method and pharmaceutical composition
|
|
JP6531166B2
(en)
|
2014-09-10 |
2019-06-12 |
メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ |
Pyrrolobenzodiazepine and its conjugate
|
|
GB201416112D0
(en)
|
2014-09-12 |
2014-10-29 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
|
SG11201701128YA
(en)
|
2014-09-12 |
2017-03-30 |
Genentech Inc |
Cysteine engineered antibodies and conjugates
|
|
JP6622293B2
(en)
|
2014-09-12 |
2019-12-18 |
ジェネンテック， インコーポレイテッド |
Anthracycline disulfide intermediates, antibody-drug conjugates, and methods
|
|
PE20170905A1
(en)
|
2014-09-17 |
2017-07-12 |
Genentech Inc |
PYROLOBENZODIAZEPINES AND ANTIBODY-DISULFIDE CONJUGATES THEREOF
|
|
JP6878287B2
(en)
|
2014-11-25 |
2021-05-26 |
アーデーセー セラピューティクス ソシエテ アノニム |
Pyrrolobenzodiazepine-antibody conjugate
|
|
WO2016090050A1
(en)
|
2014-12-03 |
2016-06-09 |
Genentech, Inc. |
Quaternary amine compounds and antibody-drug conjugates thereof
|
|
GB201506411D0
(en)
|
2015-04-15 |
2015-05-27 |
Bergenbio As |
Humanized anti-axl antibodies
|
|
GB201506402D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
MA43345A
(en)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
|
|
MA43354A
(en)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE
|
|
MA45326A
(en)
|
2015-10-20 |
2018-08-29 |
Genentech Inc |
CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
|
|
GB201601431D0
(en)
|
2016-01-26 |
2016-03-09 |
Medimmune Ltd |
Pyrrolobenzodiazepines
|
|
GB201602356D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
|
GB201602359D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
|
CN108700598A
(en)
|
2016-03-25 |
2018-10-23 |
豪夫迈·罗氏有限公司 |
The drug of the total antibody of multichannel and antibody conjugate quantifies measuring method
|
|
GB201607478D0
(en)
|
2016-04-29 |
2016-06-15 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
|
GB201608197D0
(en)
*
|
2016-05-10 |
2016-06-22 |
Ducentis Biotherapeutics Ltd |
Novel proteins
|
|
WO2017201449A1
(en)
|
2016-05-20 |
2017-11-23 |
Genentech, Inc. |
Protac antibody conjugates and methods of use
|
|
WO2017205741A1
(en)
|
2016-05-27 |
2017-11-30 |
Genentech, Inc. |
Bioanalytical method for the characterization of site-specific antibody-drug conjugates
|
|
CN109476648B
(en)
|
2016-06-06 |
2022-09-13 |
豪夫迈·罗氏有限公司 |
Sevelamer antibody-drug conjugates and methods of use
|
|
WO2018031662A1
(en)
|
2016-08-11 |
2018-02-15 |
Genentech, Inc. |
Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
|
|
JP7050770B2
(en)
|
2016-10-05 |
2022-04-08 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Method for preparing antibody drug conjugate
|
|
GB201617466D0
(en)
|
2016-10-14 |
2016-11-30 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
|
ES2871001T3
(en)
|
2017-02-08 |
2021-10-28 |
Adc Therapeutics Sa |
Conjugates of pyrrolobenzodiazepines and antibodies
|
|
GB201702031D0
(en)
|
2017-02-08 |
2017-03-22 |
Medlmmune Ltd |
Pyrrolobenzodiazepine-antibody conjugates
|
|
WO2018157773A1
(en)
*
|
2017-02-28 |
2018-09-07 |
暨南大学 |
Repair peptide for use in promoting post-traumatic tissue repair and regeneration, and application thereof
|
|
KR102189731B1
(en)
|
2017-04-18 |
2020-12-11 |
메드임뮨 리미티드 |
Pyrrolobenzodiazepine conjugate
|
|
MX2019012464A
(en)
|
2017-04-20 |
2019-12-11 |
Adc Therapeutics Sa |
Combination therapy with an anti-axl antibody-drug conjugate.
|
|
BR112019026564A2
(en)
|
2017-06-14 |
2020-06-30 |
Adc Therapeutics Sa |
dosing regimens for administration of an anti-cd19 adc
|
|
FR3069156B1
(en)
*
|
2017-07-21 |
2019-08-09 |
Universite de Bordeaux |
CLUSTERINE FOR ITS USE IN THE TREATMENT OF THROMBOTIC MICRO-ANGIOPATHIES
|
|
AU2018316532B2
(en)
|
2017-08-18 |
2022-11-24 |
Medimmune Limited |
Pyrrolobenzodiazepine conjugates
|
|
IL273387B2
(en)
|
2017-09-20 |
2023-10-01 |
Ph Pharma Co Ltd |
Thailanstatin analogs
|
|
GB201803342D0
(en)
|
2018-03-01 |
2018-04-18 |
Medimmune Ltd |
Methods
|
|
GB201806022D0
(en)
|
2018-04-12 |
2018-05-30 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
|
JP7708662B2
(en)
|
2018-10-24 |
2025-07-15 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Conjugated chemical degraders and methods of use
|
|
CN113227119A
(en)
|
2018-12-10 |
2021-08-06 |
基因泰克公司 |
Photocrosslinked peptides for site-specific conjugation to Fc-containing proteins
|
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
|
KR102890251B1
(en)
|
2019-03-15 |
2025-11-25 |
메드임뮨 리미티드 |
Azetidobenzodiazepine dimers and conjugates comprising the same for use in the treatment of cancer
|
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
|
EP4426727A2
(en)
|
2021-11-03 |
2024-09-11 |
Hangzhou Dac Biotech Co., Ltd. |
Specific conjugation of an antibody
|
|
TW202432187A
(en)
|
2022-12-23 |
2024-08-16 |
美商建南德克公司 |
Cereblon degrader conjugates, and uses thereof
|
|
CN121263210A
(en)
|
2023-04-17 |
2026-01-02 |
沛科生物公司 |
Antibodies and antibody-drug conjugates, as well as their usage, synthesis processes, and intermediates
|
|
WO2026006688A2
(en)
|
2024-06-28 |
2026-01-02 |
Firefly Bio, Inc. |
Degrader antibody conjugates and uses thereof
|
|
WO2026006689A2
(en)
|
2024-06-28 |
2026-01-02 |
Firefly Bio, Inc. |
Bcl-xl degrader antibody conjugates and uses thereof
|